Literature DB >> 25852966

Immunoglobulin Resistance in Kawasaki Disease.

Georgios A Hartas1, Syed Shahrukh Hashmi2, Chi Pham-Peyton3, Emmanouil Tsounias1, John T Bricker1, Monesha Gupta-Malhotra1.   

Abstract

Background: The aim of this study was to identify risk factors for immunoglobulin resistance, including clinical symptoms such as arthritis and the pH of intravenous immunoglobulin.
Methods: The data of children with Kawasaki disease who had received immunoglobulin were evaluated. Data regarding the brand of immunoglobulin administered were abstracted from the pharmacy records.
Results: Eighty consecutive children with Kawasaki disease were evaluated (Mdnage=28 months, 66% male). The prevalence of immunoglobulin resistance was 30%. Arthritis was a presenting symptom in the acute phase of Kawasaki disease in 8% (6/80, all male) and was seen in significant association with immunoglobulin resistance in comparison to those without arthritis (16.7% vs. 0.2%, p=0.008). Next, the immunoglobulin brand types were divided into two groups: the relatively high pH group (n=16), including Carimune (pH 6.6±0.2), and the low pH group (n=63), including Gamunex (pH 4-4.5) or Privigen (pH 4.6-5). Overall, no significant difference in immunoglobulin responsiveness was found between the low pH and the high pH groups (73% vs. 56%, p=0.193), although the low pH group showed a trend toward a larger decrease in erythrocyte sedimentation rate (p=0.048), lower steroid use (p=0.054), and lower coronary involvement (p=0.08) than those in the high pH group. Conclusions: Children presenting with arthritis in the acute phase of Kawasaki disease may be at risk for immunoglobulin resistance.

Entities:  

Year:  2015        PMID: 25852966      PMCID: PMC4365508          DOI: 10.1089/ped.2014.0423

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol Pulmonol        ISSN: 2151-321X            Impact factor:   1.349


  47 in total

1.  Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.

Authors:  M Fukunishi; M Kikkawa; K Hamana; T Onodera; K Matsuzaki; Y Matsumoto; J Hara
Journal:  J Pediatr       Date:  2000-08       Impact factor: 4.406

2.  Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.

Authors:  M Miura; H Ohki; T Tsuchihashi; H Yamagishi; Y Katada; K Yamada; Y Yamashita; A Sugaya; O Komiyama; H Shiro
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

3.  Prediction of responsiveness or non-responsiveness to treatment of acute Kawasaki disease using 1 gram per kilogram of immunoglobulin--an effective and cost-saving schedule of therapy.

Authors:  Ko Ichihashi; Hirohiko Shiraishi; Mariko Momoi
Journal:  Cardiol Young       Date:  2009-03-10       Impact factor: 1.093

4.  Novel predictors of intravenous immunoglobulin resistance in Chinese children with Kawasaki disease.

Authors:  Pei-pei Fu; Zhong-dong Du; Yue-song Pan
Journal:  Pediatr Infect Dis J       Date:  2013-08       Impact factor: 2.129

5.  Resistant Kawasaki disease treated with anti-CD20.

Authors:  Emilie Sauvaget; Béatrice Bonello; Marion David; Brigitte Chabrol; Jean-Christophe Dubus; Emmanuelle Bosdure
Journal:  J Pediatr       Date:  2012-02-17       Impact factor: 4.406

6.  Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.

Authors:  Kimiyasu Egami; Hiromi Muta; Masahiro Ishii; Kenji Suda; Yoko Sugahara; Motofumi Iemura; Toyojiro Matsuishi
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

7.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

8.  Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.

Authors:  Angela C Wooditch; Stephen C Aronoff
Journal:  Pediatrics       Date:  2005-10       Impact factor: 7.124

9.  Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. A comparative study.

Authors:  T W Jungi; M Santer; P G Lerch; S Barandun
Journal:  Vox Sang       Date:  1986       Impact factor: 2.144

10.  The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.

Authors:  Ho-Chang Kuo; Kuender D Yang; Chi-Di Liang; Chin-Nam Bong; Hong-Ren Yu; Lin Wang; Chih-Lu Wang
Journal:  Pediatr Allergy Immunol       Date:  2007-06       Impact factor: 6.377

View more
  3 in total

Review 1.  Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases.

Authors:  Xuan Li; Ye Chen; Yunjia Tang; Yueyue Ding; Qiuqin Xu; Lin Sun; Weiguo Qian; Guanghui Qian; Liqiang Qin; Haitao Lv
Journal:  Eur J Pediatr       Date:  2018-06-08       Impact factor: 3.183

2.  Kawasaki disease: abnormal initial echocardiogram is associated with resistance to IV Ig and development of coronary artery lesions.

Authors:  Dima Chbeir; Jean Gaschignard; Ronan Bonnefoy; Constance Beyler; Isabelle Melki; Albert Faye; Ulrich Meinzer
Journal:  Pediatr Rheumatol Online J       Date:  2018-07-18       Impact factor: 3.054

3.  Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease.

Authors:  Wei Li; Li Zhang; Zhouping Wang; Xiufang He; Huimei Lin; Yanfei Wang; Jia Yuan; Xiaofei Xie; Xu Zhang; Youzhen Qin; Ping Huang
Journal:  Int J Clin Pract       Date:  2022-08-03       Impact factor: 3.149

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.